ProPublica

Journalism in the Public Interest

Cancel

UCB

UCB is a drug company based in Brussels, Belgium. Its U.S. subsidiary agreed to plead guilty in June 2011 and pay more than $34 million related to allegations that it promoted its epilepsy drug Keppra for unapproved uses.

UCB began reporting payments on food, gifts, consulting payments, travel, speaking fees and other similar exchanges as of January 2012. UCB combines all categories into a single amount.

See all UCB payments, or visit UCB's transparency page.

Notable drugs

Payment Reports

2012 Jan. to Sept.

Avg. Quarterly Total
Combination $2,389,263 $7,167,789
$2,389,263 $7,167,789

Total Payments by State

State Total
California $792,122
New York $735,483
Texas $639,469
Florida $552,520
North Carolina $375,938
Pennsylvania $337,004
Ohio $315,356
Michigan $312,721
Georgia $265,217
Arizona $260,804
New Jersey $202,295
Illinois $187,079
Alabama $176,330
Missouri $176,072
Tennessee $136,276
Indiana $131,405
Maryland $130,548
Louisiana $117,046
Minnesota $113,810
Washington $105,164
Idaho $98,247
Virginia $85,171
Oklahoma $79,037
Nevada $77,378
Wisconsin $77,293
Kentucky $71,723
Connecticut $58,410
South Carolina $56,236
Rhode Island $53,313
Colorado $52,640
Mississippi $48,479
Massachusetts $45,633
Kansas $40,057
Oregon $36,758
Arkansas $35,953
West Virginia $32,488
Puerto Rico $29,854
New Mexico $27,402
Utah $26,653
District of Columbia $18,935
Delaware $13,090
Montana $9,978
Iowa $9,598
Hawaii $6,824
Nebraska $6,651
South Dakota $1,797
Alaska $1,535
New Hampshire $1,059
Vermont $902
North Dakota $751
Maine $720
Wyoming $566